Filter posts

American Invents Act Strategies Highlighted at the IPCC Conference

By David Saravitz, Alston + Bird Day 2 of the 2012 BIO Intellectual Property Counsels’ Committee …

Biotech Patent Case Law Updates at the IPCC

By John W. Cox, Counsel at Alston+Bird LLP The Spring 2012 BIO Intellectual Property Counsels’ Committee …

Congressional Hearing on International Patent Issues: BIO Submits Comments

The House Judiciary Committee conducted a hearing on World IP Day on “International Patent Issues: …

BIO Convention 2012: Biotech IP and Tech Transfer Sessions

Recent court decisions and ongoing implementation of the America Invents Act are certain to impact …

New Patented Drugs Save Us All Money and Help Those in Dire Need

New patented drugs actually save the United States and its citizens lots of money. In …

India Compulsory License: A Times of India Article Says It's Not Helping the Poor

India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with …

Mayo v. Prometheus: BIO Statement on Supreme Court Decision

By Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization We are surprised and …

Patent "Ever-Greening": Novartis Confronts Patent Myth in India

India’s ‘increased efficacy’ patentability requirement for medicines prevents an improved form of a known drug …

BIO IP Counsels Conference Agenda Topics

Join us in Austin for BIO’s Intellectual Property Counsels Committee Conference on April 16-18.  Agenda …

Patents for Humanity

By David Kappos, Director of the United States Patent and Trademark Office (USPTO) Originally Published on …